228 related articles for article (PubMed ID: 7692128)
1. The deficient degradation of synthetic 2- and 3-methyl-branched fatty acids in fibroblasts from patients with peroxisomal disorders.
Van Veldhoven PP; Huang S; Eyssen HJ; Mannaerts GP
J Inherit Metab Dis; 1993; 16(2):381-91. PubMed ID: 7692128
[TBL] [Abstract][Full Text] [Related]
2. Phytanic acid and very long chain fatty acids in genetic peroxisomal disorders.
Molzer B; Kainz-Korschinsky M; Sundt-Heller R; Bernheimer H
J Clin Chem Clin Biochem; 1989 May; 27(5):309-14. PubMed ID: 2474624
[TBL] [Abstract][Full Text] [Related]
3. A comparative study of straight chain and branched chain fatty acid oxidation in skin fibroblasts from patients with peroxisomal disorders.
Singh H; Usher S; Johnson D; Poulos A
J Lipid Res; 1990 Feb; 31(2):217-25. PubMed ID: 1691260
[TBL] [Abstract][Full Text] [Related]
4. Studies on the oxidation of phytanic acid and pristanic acid in human fibroblasts by acylcarnitine analysis.
Verhoeven NM; Jakobs C; ten Brink HJ; Wanders RJ; Roe CR
J Inherit Metab Dis; 1998 Oct; 21(7):753-60. PubMed ID: 9819705
[TBL] [Abstract][Full Text] [Related]
5. Phytanic acid alpha-oxidation and complementation analysis of classical Refsum and peroxisomal disorders.
Poll-The BT; Skjeldal OH; Stokke O; Poulos A; Demaugre F; Saudubray JM
Hum Genet; 1989 Jan; 81(2):175-81. PubMed ID: 2463966
[TBL] [Abstract][Full Text] [Related]
6. Accumulation and defective beta-oxidation of very long chain fatty acids in Zellweger's syndrome, adrenoleukodystrophy and Refsum's disease variants.
Poulos A; Singh H; Paton B; Sharp P; Derwas N
Clin Genet; 1986 May; 29(5):397-408. PubMed ID: 2427264
[TBL] [Abstract][Full Text] [Related]
7. Immunochemical and biochemical studies of fatty acid oxidation in fibroblasts of Zellweger and X-linked adrenoleukodystrophy patients.
Reubsaet FA; Veerkamp JH; Brückwilder ML; Trijbels JM; Hashimoto T; Monnens LA
Biochim Biophys Acta; 1991 Jun; 1083(3):305-9. PubMed ID: 2049396
[TBL] [Abstract][Full Text] [Related]
8. Peroxisomal very long-chain fatty acid beta-oxidation in human skin fibroblasts: activity in Zellweger syndrome and other peroxisomal disorders.
Wanders RJ; van Roermund CW; van Wijland MJ; Heikoop J; Schutgens RB; Schram AW; Tager JM; van den Bosch H; Poll-Thé BT; Saudubray JM
Clin Chim Acta; 1987 Jul; 166(2-3):255-63. PubMed ID: 2441904
[TBL] [Abstract][Full Text] [Related]
9. Phytanic acid alpha-oxidation. Differential subcellular localization in rat and human tissues and its inhibition by nycodenz.
Singh I; Pahan K; Dhaunsi GS; Lazo O; Ozand P
J Biol Chem; 1993 May; 268(14):9972-9. PubMed ID: 8486724
[TBL] [Abstract][Full Text] [Related]
10. Metabolism of branched chain fatty acids in peroxisomal disorders.
Singh H; Usher S; Johnson D; Poulos A
J Inherit Metab Dis; 1990; 13(3):387-9. PubMed ID: 1700192
[No Abstract] [Full Text] [Related]
11. Localization of nervonic acid beta-oxidation in human and rodent peroxisomes: impaired oxidation in Zellweger syndrome and X-linked adrenoleukodystrophy.
Sandhir R; Khan M; Chahal A; Singh I
J Lipid Res; 1998 Nov; 39(11):2161-71. PubMed ID: 9799802
[TBL] [Abstract][Full Text] [Related]
12. Studies on the degradation of [U-3H]-phytanic acid and [U-3H]-pristanic acid in cultured fibroblasts from children with peroxisomal disorders.
Kase BF; Björkhem I
Scand J Clin Lab Invest; 1996 May; 56(3):211-7. PubMed ID: 8761525
[TBL] [Abstract][Full Text] [Related]
13. Peroxisomal beta-oxidation of branched chain fatty acids in human skin fibroblasts.
Singh H; Brogan M; Johnson D; Poulos A
J Lipid Res; 1992 Nov; 33(11):1597-605. PubMed ID: 1464743
[TBL] [Abstract][Full Text] [Related]
14. Formation of a novel arachidonic acid metabolite in peroxisomes.
Gordon JA; Heller SK; Rhead WJ; Watkins PA; Spector AA
Prostaglandins Leukot Essent Fatty Acids; 1995; 52(2-3):77-81. PubMed ID: 7540307
[TBL] [Abstract][Full Text] [Related]
15. Peroxisomal fatty acid beta-oxidation in relation to the accumulation of very long chain fatty acids in cultured skin fibroblasts from patients with Zellweger syndrome and other peroxisomal disorders.
Wanders RJ; van Roermund CW; van Wijland MJ; Schutgens RB; Heikoop J; van den Bosch H; Schram AW; Tager JM
J Clin Invest; 1987 Dec; 80(6):1778-83. PubMed ID: 3680527
[TBL] [Abstract][Full Text] [Related]
16. A new peroxisomal beta-oxidation disorder in twin neonates: defective oxidation of both cerotic and pristanic acids.
Christensen E; Pedersen SA; Leth H; Jakobs C; Schutgens RB; Wanders RJ
J Inherit Metab Dis; 1997 Sep; 20(5):658-64. PubMed ID: 9323560
[TBL] [Abstract][Full Text] [Related]
17. [Clinical biochemical and genetic aspects of peroxisome-deficient disorders].
Suzuki Y
No To Hattatsu; 1992 Mar; 24(2):194-7. PubMed ID: 1373633
[TBL] [Abstract][Full Text] [Related]
18. Identification of three distinct peroxisomal protein import defects in patients with peroxisome biogenesis disorders.
Slawecki ML; Dodt G; Steinberg S; Moser AB; Moser HW; Gould SJ
J Cell Sci; 1995 May; 108 ( Pt 5)():1817-29. PubMed ID: 7544797
[TBL] [Abstract][Full Text] [Related]
19. Peroxisomal integral membrane proteins in livers of patients with Zellweger syndrome, infantile Refsum's disease and X-linked adrenoleukodystrophy.
Small GM; Santos MJ; Imanaka T; Poulos A; Danks DM; Moser HW; Lazarow PB
J Inherit Metab Dis; 1988; 11(4):358-71. PubMed ID: 2468817
[TBL] [Abstract][Full Text] [Related]
20. Very long-chain fatty acids in peroxisomal disease.
Poulos A; Beckman K; Johnson DW; Paton BC; Robinson BS; Sharp P; Usher S; Singh H
Adv Exp Med Biol; 1992; 318():331-40. PubMed ID: 1378993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
